Overview

A Phase 1 Study to Evaluate the Safety, Tolerability, PK/PD of SRSD107 in Healthy Participants

Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate safety and tolerability data when SRSD107 is administered as single and multiple SC injections to healthy participants. This information, along with PK/PD data, will help establish the appropriate doses and dosing regimen for future studies in patients.
Phase:
Phase 1
Details
Lead Sponsor:
Sirius Therapeutics Co., Ltd.